panbronchiolitis%20-%20diffuse
PANBRONCHIOLITIS - DIFFUSE
Diffuse panbronchiolitis is an inflammatory disease affecting the respiratory bronchioles.
It causes progressive suppurative and obstructive respiratory disease.
This is an idiopathic disease which is primarily found in Japan, Korea and China.
Predisposition to the disease may be genetically-related but environmental factors should also be considered.
Failure to treat diffuse panbronchiolitis can lead to development of bronchiectasis, progressive failure and death.

Introduction

  • This is an idiopathic disease which is primarily found in Japan, Korea & China
  • Predisposition to the disease may be genetically-related but environmental factors should also be considered
  • Failure to treat diffuse panbronchiolitis (DPB) leads to development of widespread bronchiectasis, progressive respiratory failure & death

Epidemiology

  • More common in 2nd-5th decade of life
  • Not related to smoking & exposure to toxic fumes
  • High incidence in Asian countries (Japan, Korea, Taiwan, Malaysia, China, Thailand, Singapore)

Definition

  • Inflammatory disease affecting the respiratory bronchioles
  • Causes progressive suppurative & obstructive respiratory disease

Signs and Symptoms

  • Chronic paranasal sinusitis (>80%)
  • Productive cough which usually occurs in the 2nd-5th decade of life
  • Wheezing
  • Dyspnea on exertion
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
22 May 2017
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.